BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gabr A, Kulik L, Mouli S, Riaz A, Ali R, Desai K, Mora RA, Ganger D, Maddur H, Flamm S, Boike J, Moore C, Thornburg B, Alasadi A, Baker T, Borja-Cacho D, Katariya N, Ladner DP, Caicedo JC, Lewandowski RJ, Salem R. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. Hepatology 2021;73:998-1010. [PMID: 32416631 DOI: 10.1002/hep.31318] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 Johnson GE, Padia SA. Yttrium-90 Radiation Segmentectomy. Semin Intervent Radiol 2020;37:537-42. [PMID: 33328710 DOI: 10.1055/s-0040-1720953] [Reference Citation Analysis]
2 Moris D, Shaw BI, McElroy L, Barbas AS. Using Hepatocellular Carcinoma Tumor Burden Score to Stratify Prognosis after Liver Transplantation. Cancers (Basel) 2020;12:E3372. [PMID: 33202588 DOI: 10.3390/cancers12113372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Qadan M, Fong ZV, Delman AM, Gabr A, Salem R, Shah SA. Review of Use of Y90 as a Bridge to Liver Resection and Transplantation in Hepatocellular Carcinoma. J Gastrointest Surg 2021. [PMID: 34345997 DOI: 10.1007/s11605-021-05095-x] [Reference Citation Analysis]
4 Shah MB, Villagomez Rubio DA, Orozco G, Desai S, Ancheta A, Gupta M, Mei X, Evers BM, Gedaly R, Cannon RM. Outcomes in Elderly Patients Undergoing Liver Transplantation Compared with Liver-Directed Ablative Therapy in Early-Stage Hepatocellular Carcinoma. Journal of the American College of Surgeons 2022;234:892-9. [DOI: 10.1097/xcs.0000000000000135] [Reference Citation Analysis]
5 Crocetti L, Bozzi E, Scalise P, Bargellini I, Lorenzoni G, Ghinolfi D, Campani D, Balzano E, De Simone P, Cioni R. Locoregional Treatments for Bridging and Downstaging HCC to Liver Transplantation. Cancers (Basel) 2021;13:5558. [PMID: 34771720 DOI: 10.3390/cancers13215558] [Reference Citation Analysis]
6 Swersky A, Kulik L, Kalyan A, Grace K, Caicedo JC, Lewandowski RJ, Salem R. Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach. Semin Intervent Radiol 2021;38:432-7. [PMID: 34629710 DOI: 10.1055/s-0041-1735528] [Reference Citation Analysis]
7 Tabori NE, Sivananthan G. Treatment Options for Early-Stage Hepatocellular Carcinoma. Semin Intervent Radiol 2020;37:448-55. [PMID: 33328700 DOI: 10.1055/s-0040-1720950] [Reference Citation Analysis]
8 De la Garza-Ramos C, Overfield CJ, Montazeri SA, Liou H, Paz-Fumagalli R, Frey GT, McKinney JM, Ritchie CA, Devcic Z, Lewis AR, Harnois DM, Patel T, Toskich BB. Biochemical Safety of Ablative Yttrium-90 Radioembolization for Hepatocellular Carcinoma as a Function of Percent Liver Treated. J Hepatocell Carcinoma 2021;8:861-70. [PMID: 34368021 DOI: 10.2147/JHC.S319215] [Reference Citation Analysis]
9 Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology 2021;74:2342-52. [PMID: 33739462 DOI: 10.1002/hep.31819] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 50.0] [Reference Citation Analysis]
10 Zhao X, Sun X, Huang W, Chen R, Chen K, Nie L, Fang C. A microenvironment-responsive FePt probes for imaging-guided Fenton-enhanced radiotherapy of hepatocellular carcinoma. J Nanobiotechnology 2022;20:100. [PMID: 35241082 DOI: 10.1186/s12951-022-01305-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Guiu B, Garin E, Allimant C, Edeline J, Salem R. TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. Cardiovasc Intervent Radiol 2022. [PMID: 35149884 DOI: 10.1007/s00270-022-03072-8] [Reference Citation Analysis]
12 Salem R, Gabr A. Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database. J Nucl Med 2022;63:57-8. [PMID: 34916247 DOI: 10.2967/jnumed.121.262917] [Reference Citation Analysis]
13 Bargellini I, Boni G, Traino AC, Bozzi E, Lorenzoni G, Bianchi F, Cervelli R, Depalo T, Crocetti L, Volterrani D, Cioni R. Management of Liver Tumors during the COVID-19 Pandemic: The Added Value of Selective Internal Radiation Therapy (SIRT). J Clin Med 2021;10:4315. [PMID: 34640332 DOI: 10.3390/jcm10194315] [Reference Citation Analysis]
14 Salem R, Li D, Sommer N, Hernandez S, Verret W, Ding B, Lencioni R. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial. Cancer Med 2021;10:5437-47. [PMID: 34189869 DOI: 10.1002/cam4.4090] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Frantz S, Matsuoka L, Vaheesan K, Petroziello M, Golzarian J, Wang E, Gandhi R, Collins Z, Brower J, Rachakonda VM, Du L, Kennedy AS, Sze DY, Lee J, Brown DB. Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry. J Vasc Interv Radiol 2021;32:845-52. [PMID: 33812981 DOI: 10.1016/j.jvir.2021.03.535] [Reference Citation Analysis]
16 Montazeri SA, De la Garza-Ramos C, Lewis AR, Lewis JT, LeGout JD, Sella DM, Paz-Fumagalli R, Devcic Z, Ritchie CA, Frey GT, Vidal L, Croome KP, McKinney JM, Harnois D, Krishnan S, Patel T, Toskich BB. Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors. Eur J Nucl Med Mol Imaging 2022. [PMID: 35441860 DOI: 10.1007/s00259-022-05776-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Esagian SM, Kakos CD, Giorgakis E, Burdine L, Barreto JC, Mavros MN. Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers (Basel) 2021;13:2984. [PMID: 34203692 DOI: 10.3390/cancers13122984] [Reference Citation Analysis]
18 Xu L, Chen L, Zhang W. Neoadjuvant treatment strategies for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(12): 1550-1566 [DOI: 10.4240/wjgs.v13.i12.1550] [Reference Citation Analysis]
19 Zane KE, Nagib PB, Jalil S, Mumtaz K, Makary MS. Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma. World J Hepatol 2022; 14(5): 885-895 [DOI: 10.4254/wjh.v14.i5.885] [Reference Citation Analysis]
20 Miller FH, Lopes Vendrami C, Gabr A, Horowitz JM, Kelahan LC, Riaz A, Salem R, Lewandowski RJ. Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. Radiographics 2021;41:1802-18. [PMID: 34559587 DOI: 10.1148/rg.2021210014] [Reference Citation Analysis]
21 Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021;18:3066-81. [PMID: 34400877 DOI: 10.7150/ijms.59930] [Reference Citation Analysis]
22 Sivananthan G, Tabori NE. Principles of Radioembolization. Semin Intervent Radiol 2021;38:393-6. [PMID: 34629704 DOI: 10.1055/s-0041-1735606] [Reference Citation Analysis]
23 Gill H, Hiller J. Systematic review of lung shunt fraction quantification comparing SPECT/CT and planar scintigraphy for yttrium 90 radioembolization planning. Clin Transl Imaging 2021;9:181-8. [DOI: 10.1007/s40336-021-00417-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, Salem R. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging 2021;48:580-3. [DOI: 10.1007/s00259-020-04976-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]